Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
NCT00270452
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
NIH
Sponsor class
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG:
WT1 and PR1 Peptide Vaccine
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)